Published: 26th July 2024
By: Value Research
Mankind Pharma, known for consumer health brands like Manforce Condoms, Prega News & Glucon-D, will acquire Bharat Serums and Vaccines (BSV) from PE giant Advent International for Rs 13,630 crore.
As per Mankind, the acquisition will provide it access to BSV’s high-entry barrier complex portfolio in women’s health, fertility, critical care and Immunoglobulin segments.
With highly sophisticated in-house R&D tech platforms, BSV boasts a robust branded product portfolio across women's health, fertility and critical care.
BSV’s portfolio is differentiated and difficult to enter into as complex biologics require at least 5 to 10 years of R&D for development.
With BSV’s portfolio under its belt, Mankind is expecting to be a leader in India’s women's health & fertility market. Their combined sales corner the highest market share of 13% in gynaecology.
Mankind will fund the acquisition through internal accruals and a mix of debt and equity. The deal is expected to close in the next 3-4 months subject to regulatory approvals.
You can check Mankind Pharma’s financial track record and key ratios from the link below.